Aethlon Medical posts corporate presentation on Hemopurifier platform targeting cancer, viral threats, transplant

Aethlon Medical

Aethlon Medical

AEMD

0.00
  • Aethlon Medical outlined progress for its Hemopurifier blood-filtration platform targeting cancer, viral threats, and transplant-related applications.
  • Australian oncology study: cohorts 1-2 complete; cohort 3 open; first patient treated in June 2026; no dose-limiting toxicities reported.
  • Upcoming catalysts flagged within 6-9 months, including central lab readouts on extracellular vesicle removal, CD8 T-cell changes, and safety.
  • Corporate overview cited about $5 million cash at March 31, 2026; no outstanding debt; about 2,400,000 shares outstanding as of June 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.